Vanguard Group Inc. Makes New $22.56 Million Investment in Septerna, Inc. (NASDAQ:SEPN)

Vanguard Group Inc. bought a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 985,032 shares of the company's stock, valued at approximately $22,557,000. Vanguard Group Inc. owned approximately 2.22% of Septerna as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. bought a new stake in shares of Septerna during the 4th quarter worth about $3,197,000. Bank of New York Mellon Corp bought a new stake in Septerna during the fourth quarter worth approximately $872,000. Lindbrook Capital LLC acquired a new position in Septerna during the fourth quarter valued at approximately $481,000. Rhumbline Advisers bought a new position in shares of Septerna in the fourth quarter valued at approximately $458,000. Finally, M&T Bank Corp acquired a new stake in shares of Septerna in the fourth quarter worth $376,000.

Insider Activity

In related news, CFO Gil M. Labrucherie acquired 5,000 shares of the firm's stock in a transaction on Friday, February 21st. The shares were bought at an average cost of $5.85 per share, with a total value of $29,250.00. Following the completion of the acquisition, the chief financial officer now owns 30,000 shares of the company's stock, valued at $175,500. This trade represents a 20.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Alan Ezekowitz purchased 41,355 shares of the stock in a transaction on Thursday, March 6th. The stock was bought at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the transaction, the director now directly owns 104,101 shares of the company's stock, valued at approximately $624,606. This trade represents a 65.91 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 74,346 shares of company stock worth $439,670.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Wells Fargo & Company cut their target price on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research report on Friday, March 28th. Cantor Fitzgerald reissued an "overweight" rating and set a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Price Performance

NASDAQ SEPN traded down $0.09 during midday trading on Friday, hitting $5.90. The company had a trading volume of 211,957 shares, compared to its average volume of 439,031. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The stock has a fifty day moving average of $6.56.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The firm had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, sell-side analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.